Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study of NGM282 in Patients With Primary Sclerosing Cholangitis

ClinicalTrials.gov ID: NCT02704364

Public ClinicalTrials.gov record NCT02704364. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 8:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis

Study identification

NCT ID
NCT02704364
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Enrollment
62 participants

Conditions and interventions

Interventions

  • NGM282 Biological
  • Placebo Other

Biological · Other

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 29, 2016
Primary completion
May 31, 2017
Completion
May 31, 2017
Last update posted
Jun 16, 2025

2016 – 2017

United States locations

U.S. sites
26
U.S. states
14
U.S. cities
24
Facility City State ZIP Site status
NGM Clinical Study Site 118 Sacramento California
NGM Clinical Study Site 112 San Clemente California
NGM Clinical Study Site 127 San Francisco California
NGM Clinical Study Site 106 Aurora Colorado
NGM Clinical Study Site 115 Washington D.C. District of Columbia
NGM Clinical Study Site 110 Gainesville Florida
NGM Clinical Study Site 124 Lakewood Rch Florida
NGM Clinical Study Site 105 Miami Florida
NGM Clinical Study Site 109 Indianapolis Indiana
NGM Clinical Study Site 104 Detroit Michigan
NGM Clinical Study Site 102 Kansas City Missouri
NGM Clinical Study Site 107 St Louis Missouri
NGM Clinical Study Site 103 New York New York
NGM Clinical Study Site 116 Durham North Carolina
NGM Clinical Study Site 120 Cincinnati Ohio
NGM Clinical Study Site 114 Nashville Tennessee
NGM Clinical Study Site 113 Dallas Texas
NGM Clinical Study Site 117 Dallas Texas
NGM Clinical Study Site 119 Houston Texas
NGM Clinical Study Site 125 Southlake Texas
NGM Clinical Study Site 111 Charlottesville Virginia
NGM Clinical Study Site 122 Newport News Virginia
NGM Clinical Study Site 101 Norfolk Virginia
NGM Clinical Study Site 121 Richmond Virginia
NGM Clinical Study Site 108 Seattle Washington
NGM Clinical Study Site 126 Seattle Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02704364, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 16, 2025 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02704364 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →